The findings, published in The Lancet Respiratory Medicine, suggest that dupilumab, when used alongside standard triple ...

Atopic dermatitis (AD) is a very common, heterogeneous and debilitating disease with a need for new treatment options CAN10 ...

Sanofi and Regeneron's Dupixent (dupilumab) has gained approval from the FDA for chronic spontaneous urticaria (CSU) ...

The CSU indication is the seventh disease driven in part by underlying type 2 inflammation in which Dupixent has received approval.

The U.S. Food and Drug Administration has approved Dupixent (dupilumab) for the treatment of adults and adolescents with ...

Children with atopic dermatitis are more likely to develop uveitis than children without it, especially if the dermatitis is severe.

Dupixent approved in the US as the first new targeted therapy in over a decade for chronic spontaneous urticaria Approval based on phase 3 studies demonstrating Dupixent significantly reduced itch and ...

First quarter 2025 revenues of $3.0 billion; GAAP diluted EPS of $7.27 and non-GAAP diluted EPS(a) of $8.22First quarter 2025 Dupixent® global net sales (recorded by Sanofi) increased 19% to $3.67 bil ...

Spring starts with the time change, and while it's nice now to have hours of additional sunlight every day, losing that hour ...

French pharma major Sanofi delivered a set of first-quarter financial results that seemed to satisfy markets Thursday, as its ...

But thankfully other monoclonal antibodies are showing promise for allergy treatment, including Dupilumab (Dupixent) and REGN 1908-1909, hopefully hinting that more options are on the horizon.